Innova Captab Limited has witnessed a significant shareholding change as Vistra ITCL (India) Limited acquired a stake through a non-disposal undertaking arrangement. The transaction was disclosed under SEBI's substantial acquisition regulations, representing a notable development in the company's shareholding pattern.

Acquisition Details

The acquisition involved 18,75,000 equity shares of Innova Captab Limited, representing 3.28% of the company's total share capital. Vistra ITCL, operating in its capacity as Debenture Trustee/Security Trustee, completed the transaction through a non-disposal undertaking mechanism on March 24, 2026.

Pre and Post Acquisition Holdings

Prior to this transaction, Vistra ITCL held no shares or voting rights in Innova Captab Limited. The acquisition represents the company's initial investment in the target company through the encumbrance route.

Company Information

Innova Captab Limited's equity share capital comprises 18,75,000 equity shares with a face value of ₹10 each, aggregating to ₹1,87,50,000. The company's shares are listed on both BSE Limited and National Stock Exchange of India Limited.

Vistra ITCL (India) Limited, headquartered at The Qube in Mumbai's Andheri East, does not belong to the promoter or promoter group of Innova Captab Limited. The company is acting specifically in its capacity as Debenture Trustee/Security Trustee for this transaction.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The notification was submitted to both stock exchanges where Innova Captab's shares are traded, ensuring full regulatory transparency. As per SEBI guidelines, while the primary compliance responsibility lies with the lender or debenture holder, Vistra ITCL filed this disclosure out of abundant caution in its trustee capacity.

Innova Captab Limited has announced its participation in an analyst and investor meeting scheduled for March 9, 2026, as part of the Investec Promoter & Founder Conference 2026. The pharmaceutical company informed stock exchanges about this engagement through a regulatory filing dated March 3, 2026.

Meeting Details and Schedule

The investor interaction is structured to facilitate comprehensive engagement between company representatives and market participants. The meeting will provide opportunities for both individual and group discussions with analysts and institutional investors.

Regulatory Compliance and Information Sharing

The company has emphasized its commitment to regulatory compliance and transparent information sharing practices. Innova Captab Limited has specifically stated that all discussions during the meeting will be based exclusively on publicly available information. The company has assured that no unpublished price-sensitive information will be shared with analysts or investors during these interactions.

Important Disclaimers

The pharmaceutical company has included important caveats regarding the scheduled meeting. The meeting schedule remains subject to potential changes due to exigencies that may arise from either the host organization or the company itself. This flexibility ensures that any unforeseen circumstances can be accommodated while maintaining professional engagement standards.

The announcement was signed by Neeharika Shukla, Company Secretary and Compliance Officer, demonstrating proper corporate governance protocols in investor relations activities.